Exploring the anti-SARS-CoV-2 main protease potential of FDA approved marine drugs using integrated machine learning templates as predictive toolsArticle Published on 2022-11-012022-11-15 Journal: International journal of biological macromolecules [Category] SARS, 신약개발, 치료제, [키워드] activity Activity atlas model Activity cliff Algorithm anti-SARS-CoV-2 approved Atla Biological camostat Compound COVID-19 COVID-19 pandemic Cresset data set docked drug drugs effective FDA field Field template FIVE flare group Holichondrin B inactive macromolecules Marine drugs. nafamostat outbreak Predictive protease Protein remained Repurposed drug responsible Safe SARS-CoV-2 Structure structures [DOI] 10.1016/j.ijbiomac.2022.09.086 PMC 바로가기
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2Article Published on 2022-10-262023-07-10 Journal: Microbiology Spectrum [Category] COVID19(2023년), [키워드] Antiviral Calu-3 camostat Combination coronavirus DAA directly acting antiviral drug combinations Ebola host-targeting antiviral HTA molnupiravir Paxlovid SARS-CoV-2 synergy variant(s) of concern. [DOI] 10.1128/spectrum.03331-22 PMC 바로가기
Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2막횡단 세린 프로테아제 TMPRSS2를 중심으로 SARS-CoV-2에 의해 유도된 후각장애와 관련된 분자 기전Review Published on 2022-10-012022-09-11 Journal: Archives of Virology [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] Anosmia Apoptosis blockade camostat caused cell entry cellular and molecular chromosome chromosome 21 cleaving Delta dependent on disease disorder dysfunction entry of SARS-CoV-2 event ExoN exons facilitate functional gene encoding Genetic variations help host cell Inflammation involved mechanism nafamostat neuronal number of symptoms olfactory dysfunction olfactory neuroepithelium omicron overcome pandemic virus receptor receptors risk SARS-CoV-2 Serine serine protease serine protease inhibitor serine protease inhibitors shown strain Strains Symptoms therapeutic TMPRSS2 transmembrane serine protease viral S protein virus [DOI] 10.1007/s00705-022-05545-0 PMC 바로가기 [Article Type] Review
A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)Article Published on 2022-09-272022-11-15 Journal: BMC Medicine [Category] SARS, 진단, [키워드] 95% confidence interval Administered age airway analysis asymptomatic patients Bayesian camostat camostat mesilate cardiovascular diseases cells Chronic kidney disease chronic respiratory disease clinical conducted consecutive negative test conversion COVID-19 COVID-19 symptom Diabetes Mellitus dose double-blind Drug screening effective Efficacy and safety eight enrolled evaluate Factor first test hospital human airway epithelial hypertension indicated Japan median time Mild moderate multicenter no significant difference obesity parallel-group Patient patients patients with COVID-19 Placebo placebo-controlled study Positive test Prevent primary efficacy endpoint Randomized Randomized controlled trial receive reduce registry SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2. the placebo group the primary endpoint Treatment two groups underlying disease viral clearance viral loads was performed were blinded were excluded without symptoms [DOI] 10.1186/s12916-022-02518-7 PMC 바로가기
Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trialClinical Trial Published on 2022-09-012022-10-04 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 95% confidence interval adverse event analysis antiviral drug assigned asymptomatic patient camostat Camostat mesylate Clinical improvement conducted Confirmed COVID-19 infection COVID-19 COVID-19 disease Cox regression cycle threshold distribution early phase effective Efficacy Efficacy and safety Frequency hazard ratio nasopharyngeal viral load Neutralizing antibodies Neutralizing antibody titer participant performed Placebo placebo group placebo-controlled protocol Randomized Randomized controlled trial Randomly receive Safety Safety. SARS-CoV-2 symptomatic treat Treatment Trial two groups [DOI] 10.1016/j.ijid.2022.06.054 PMC 바로가기 [Article Type] Clinical Trial
Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into CellsSARS-CoV-2 세포로의 진입을 완전히 차단하려면 Vacuolar-ATPase 및 TMPRSS2의 이중 억제가 필요합니다Article Published on 2022-07-192022-09-11 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] absence Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 ATPase bafilomycin block viral entry camostat cathepsin inhibitor Cathepsins Cell cellular Compound coronavirus E64d Efficacy endosomal pH endosomal protease endosome expressing highlight host cell host protease host proteases Hydroxychloroquine identify implicated Infection inhibit inhibiting inhibition inhibitor inhibitors Intervention life cycle Macrolide maturation mechanisms membrane fusion molecules Neutralizing nonspecific Pathways pharmacological agent Prevent protease Protein proteolytic activation provide pseudotyped rationale S protein SARS SARS-CoV-2 SARS-CoV-2 entry SARS-COV-2 infection Serine serine 2 serine proteases severe acute respiratory syndrome Coronavirus synergy the S protein these compound these compounds TMPRSS2 TMPRSS2 inhibitor TMPRSS2-expressing cells toxicities Toxicity transmembrane V-ATPase viral entry viral spike virus virus. [DOI] 10.1128/aac.00439-22 PMC 바로가기 [Article Type] Article
Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell cultureTMPRSS2의 펩티드모방 억제제는 세포 배양에서 SARS-CoV-2 감염을 차단합니다Article Published on 2022-07-082022-09-11 Journal: Communications Biology [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] antiviral agent Antiviral agents Blood camostat Camostat mesylate candidate catalytic site Cell culture clinical development Coagulation comparable Compound COVID-19 COVID-19 therapy Delta Efficacy electrophilic host cell in silico in vitro inhibit inhibit SARS-CoV-2 inhibitors of TMPRSS2 molecular docking studies Molecular docking study omicron plasma Prevent Proteases Protein pseudovirus entry SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant selected Serine serum and plasma spike target the SARS-CoV-2 therapy TMPRSS2 TMPRSS2 inhibitor TMPRSS2 inhibitors transmembrane serine protease transmembrane serine protease 2 TRAP viruses [DOI] 10.1038/s42003-022-03613-4 PMC 바로가기 [Article Type] Article
Mechanistic insights of key host proteins and potential repurposed inhibitors regulating SARS-CoV-2 pathwaySARS-CoV-2 경로를 조절하는 주요 숙주 단백질 및 잠재적 용도 변경 억제제에 대한 기계론적 통찰력Article Published on 2022-07-052022-09-11 Journal: Journal of computational chemistry [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] acute respiratory syndrome camostat catalytic activity Clinical studies clinical study develop dissociation pathways drug drugs Efficacy eIF4E2 energetics finding HDAC2 Host host protein host proteins independent inhibitor inhibitors inhibitory involved Keeping Kinetics mechanism mechanisms Metadynamics molecular molecular dynamics molecular dynamics. MOST nafamostat pandemic paper pathway Pathways Patient Probability Protein Repurposed drugs residue residues SARS-CoV-2 Severe acute respiratory syndrome severe COVID-19 patients Silmitasertib Support target targets treat Vaccine Valproic acid variant Zotatifin [DOI] 10.1002/jcc.26888 PMC 바로가기 [Article Type] Article
Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19COVID-19의 잠재적 치료제로서 약물 용도 변경 후보를 스크리닝하기 위한 TMPRSS2 분석 제품군Article Published on 2022-06-102022-09-11 Journal: ACS Infectious Diseases [Category] COVID19(2023년), SARS, 신약개발, 치료기술, 치료제, [키워드] ACE2 ACE2-expressing cell ACE2-expressing cells Antiviral antiviral therapeutics antiviral therapy approved drug approved drugs bind biochemical biochemical assay camostat candidate cleavage clinical trial clinical trials Compound COVID-19 COVID-19 pandemic driving drug Drug repurposing effective antiviral treatment fluorescent followed by high-throughput screening. human clinical trial human clinical trials inhibiting inhibitors of TMPRSS2 Initially Japan mass spectrometry molecule nafamostat otamixaban PCI-27483 Potential Prevent protease Protease activity pseudotyped Receptor-binding domain repurposing SARS-CoV-2 Screening Spike protein symptom onset tested the receptor-binding domain the spike protein Therapies therapy TMPRSS2 Vaccine viral entry viral pathogen [DOI] 10.1021/acsinfecdis.2c00172 PMC 바로가기 [Article Type] Article
Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trialResearch article Published on 2022-06-032022-10-05 Journal: EClinicalMedicine [Category] 신약개발, 임상, 치료제, [키워드] 95% CI Admission Adverse AMED assigned calculated camostat Characteristics Ciclesonide clinical Clinical finding Clinical management Combination combination therapy comparable COVID-19 COVID-19 infection deaths decrease development discharge Effectiveness enrolled evaluated event Favipiravir finding funding group groups healthcare worker hospital discharge rate Hospital stay Hospitalization Hospitalized Japan Japanese lack less limitation median time Ministry of Health monotherapy no significant difference number Open-label oxygen participant Patient patients patients with moderate Phase 3 phase 3 study Pneumonia positive Primary outcome randomized clinical trial Randomized controlled trial Randomly Registered registry Research SARS-CoV-2 Severe COVID-19 Infection significantly higher significantly lower single-center statistically supported therapy Treatment vaccination Version Welfare [DOI] 10.1016/j.eclinm.2022.101484 [Article Type] Research article